203 related articles for article (PubMed ID: 31435073)
1. Evaluation and management of toxicity of cytoreductive surgery/hyperthermic intraperitoneal chemotherapy: the initial experience of a single centre study.
Lemstrova R; Flasarova D; Spisarova M; Melichar B; Lovecek M; Havlik R; Neoral C; Mohelnikova-Duchonova B; Klos D
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2020 Sep; 164(3):300-306. PubMed ID: 31435073
[TBL] [Abstract][Full Text] [Related]
2. Systematic review of published literature on oxaliplatin and mitomycin C as chemotherapeutic agents for hyperthermic intraperitoneal chemotherapy in patients with peritoneal metastases from colorectal cancer.
Wisselink DD; Braakhuis LLF; Gallo G; van Grevenstein WMU; van Dieren S; Kok NFM; de Reuver PR; Tanis PJ; de Hingh IHJT
Crit Rev Oncol Hematol; 2019 Oct; 142():119-129. PubMed ID: 31400583
[TBL] [Abstract][Full Text] [Related]
3. Toxicity profile of chemotherapy agents used in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies.
Somashekhar SP; Yethadka R; Kumar C R; Ashwin KR; Zaveri S; Rauthan A
Eur J Surg Oncol; 2020 Apr; 46(4 Pt A):577-581. PubMed ID: 31677939
[TBL] [Abstract][Full Text] [Related]
4. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in pseudomyxoma peritonei of appendiceal origin: result of a single centre study.
Di Leo A; Corvasce A; Weindelmayer J; Mason EJ; Casella F; de Manzoni G
Updates Surg; 2020 Dec; 72(4):1207-1212. PubMed ID: 32410159
[TBL] [Abstract][Full Text] [Related]
5. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival for patients with peritoneal carcinomatosis from colorectal cancer: a phase II study from a Chinese center.
Huang CQ; Yang XJ; Yu Y; Wu HT; Liu Y; Yonemura Y; Li Y
PLoS One; 2014; 9(9):e108509. PubMed ID: 25259574
[TBL] [Abstract][Full Text] [Related]
6. Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for limited peritoneal metastasis. The PSOGI international collaborative registry.
Arjona-Sanchez A; Aziz O; Passot G; Salti G; Esquivel J; Van der Speeten K; Piso P; Nedelcut DS; Sommariva A; Yonemura Y; Turaga K; Selvasekar CR; Rodriguez-Ortiz L; Sanchez-Hidalgo JM; Casado-Adam A; Rufian-Peña S; Briceño J; Glehen O
Eur J Surg Oncol; 2021 Jun; 47(6):1420-1426. PubMed ID: 33298341
[TBL] [Abstract][Full Text] [Related]
7. Hyperthermic intraperitoneal chemotherapy in colorectal cancer.
Fisher OM; Brown C; Esquivel J; Larsen SG; Liauw W; Alzahrani NA; Morris DL; Kepenekian V; Sourrouille I; Dumont F; Tuech JJ; Ceribelli C; Doussot B; Sgarbura O; Alhosni M; Quenet F; Glehen O; Cashin PH;
BJS Open; 2024 May; 8(3):. PubMed ID: 38722737
[TBL] [Abstract][Full Text] [Related]
8. Iterative procedures combining cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for isolated peritoneal recurrence.
Vaira M; Robella M; Mellano A; Sottile A; De Simone M
Int J Hyperthermia; 2014 Dec; 30(8):565-9. PubMed ID: 25430988
[TBL] [Abstract][Full Text] [Related]
9. Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC).
Baratti D; Kusamura S; Cabras AD; Bertulli R; Hutanu I; Deraco M
Eur J Cancer; 2013 Oct; 49(15):3140-8. PubMed ID: 23831335
[TBL] [Abstract][Full Text] [Related]
10. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for malignant peritoneal mesothelioma.
Klos D; Hanuliak J; Lemstrova R; Mohelnikova-Duchonova B; Zapletalova J; Melichar B; Risko J
Bratisl Lek Listy; 2023; 124(5):345-350. PubMed ID: 36876363
[TBL] [Abstract][Full Text] [Related]
11. Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer: a multi-institutional study.
Deraco M; Virzì S; Iusco DR; Puccio F; Macrì A; Famulari C; Solazzo M; Bonomi S; Grassi A; Baratti D; Kusamura S
BJOG; 2012 Jun; 119(7):800-9. PubMed ID: 22571746
[TBL] [Abstract][Full Text] [Related]
12. Mitomycin-C versus oxaliplatin during cytoreductive surgery and HIPEC for peritoneal metastases secondary to colorectal carcinoma: a retrospective analysis.
Spiliotis J; Kalles V; Prodromidou A; Raptis A; Ferfelis M; Christopoulou A; Tsiatas M
J BUON; 2021; 26(4):1260-1265. PubMed ID: 34564979
[TBL] [Abstract][Full Text] [Related]
13. Open versus Closed technique for administration of heated intraperitoneal chemotherapy (HIPEC): Morbidity and Mortality outcomes from a high-volume centre.
Hassan S; Dritsas S; O'Dwyer ST; Aziz O; Sutton P; Wang X; Fish R;
Eur J Surg Oncol; 2023 Sep; 49(9):106924. PubMed ID: 37179147
[TBL] [Abstract][Full Text] [Related]
14. Long-term survival after hyperthermic intraperitoneal chemotherapy using mitomycin C or oxaliplatin in colorectal cancer patients with synchronous peritoneal metastases: A nationwide comparative study.
Bakkers C; van Erning FN; Rovers KP; Nienhuijs SW; Burger JW; Lemmens VE; Aalbers AG; Kok NF; Boerma D; Brandt AR; Hemmer PH; van Grevenstein WM; de Reuver PR; Tanis PJ; Tuynman JB; de Hingh IH
Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1902-1907. PubMed ID: 32340819
[TBL] [Abstract][Full Text] [Related]
15. 2022 Peritoneal Surface Oncology Group International Consensus on HIPEC Regimens for Peritoneal Malignancies: Colorectal Cancer.
Hübner M; van Der Speeten K; Govaerts K; de Hingh I; Villeneuve L; Kusamura S; Glehen O
Ann Surg Oncol; 2024 Jan; 31(1):567-576. PubMed ID: 37940803
[TBL] [Abstract][Full Text] [Related]
16. Exposure to Neoadjuvant Oxaliplatin-Containing Chemotherapy, Does it Effect Intraperitoneal Hyperthermic Chemotherapy Perfusion?
Mangieri CW; Valenzuela CD; Solsky IB; Erali RA; Votanopoulos KI; Shen P; Levine EA
Ann Surg Oncol; 2023 Apr; 30(4):2486-2493. PubMed ID: 36484904
[TBL] [Abstract][Full Text] [Related]
17. Safety of intraperitoneal Mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC.
van Eden WJ; Kok NFM; Woensdregt K; Huitema ADR; Boot H; Aalbers AGJ
Eur J Surg Oncol; 2018 Feb; 44(2):220-227. PubMed ID: 29258720
[TBL] [Abstract][Full Text] [Related]
18. Impact of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on systemic toxicity.
Kusamura S; Baratti D; Younan R; Laterza B; Oliva GD; Costanzo P; Favaro M; Gavazzi C; Grosso F; Deraco M
Ann Surg Oncol; 2007 Sep; 14(9):2550-8. PubMed ID: 17558537
[TBL] [Abstract][Full Text] [Related]
19. Effect of intraperitoneal chemotherapy concentration on morbidity and survival.
Elekonawo FMK; van Eden WJ; van der Plas WY; Ewalds RSG; de Jong LAW; Bremers AJA; Hemmer PHJ; Kok NFM; Kruijff S; Aalbers AGJ; de Reuver PR
BJS Open; 2020 Apr; 4(2):293-300. PubMed ID: 31950702
[TBL] [Abstract][Full Text] [Related]
20. Repeat cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent diffuse malignant peritoneal mesothelioma.
Huang Y; Alzahrani NA; Liauw W; Morris DL
Eur J Surg Oncol; 2015 Oct; 41(10):1373-8. PubMed ID: 26227745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
